EQL PHARMA AB (7JK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, EQL PHARMA AB (7JK) has a cash flow conversion efficiency ratio of 0.063x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€16.79 Million ≈ $19.63 Million USD) by net assets (€267.06 Million ≈ $312.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EQL PHARMA AB market cap and net worth for the company's overall valuation and market capitalisation.
EQL PHARMA AB - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how EQL PHARMA AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
EQL PHARMA AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of EQL PHARMA AB ranked by their cash flow conversion efficiency. Explore cash flow quality index of EQL PHARMA AB to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Outset Medical Inc
NASDAQ:OM
|
-0.100x |
|
Inversa Prime SOCIMI S.A.
MC:YIPS
|
-0.029x |
|
ONDINE BIOMEDICAL INC.CDI
F:VF5
|
N/A |
|
Newfield Resources Ltd
AU:NWF
|
0.201x |
|
Sentry Select Primary Metals Corp
TO:PME
|
0.010x |
|
EML Payments Ltd
AU:EML
|
-0.225x |
|
Gezinomi Seyahat Turizm Ticaret AS
IS:GZNMI
|
0.366x |
|
ZENTEK LTD.
F:ZAY0
|
-0.158x |
Annual Cash Flow Conversion Efficiency for EQL PHARMA AB (2022–2026)
The table below shows the annual cash flow conversion efficiency of EQL PHARMA AB from 2022 to 2026. View EQL PHARMA AB stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | €267.06 Million ≈ $312.22 Million |
€28.36 Million ≈ $33.16 Million |
0.106x | +195.22% |
| 2025-03-31 | €221.03 Million ≈ $258.41 Million |
€-24.65 Million ≈ $-28.82 Million |
-0.112x | -73.31% |
| 2024-03-31 | €177.73 Million ≈ $207.78 Million |
€-11.44 Million ≈ $-13.37 Million |
-0.064x | -136.06% |
| 2023-03-31 | €154.75 Million ≈ $180.92 Million |
€27.62 Million ≈ $32.29 Million |
0.178x | -47.26% |
| 2022-03-31 | €123.63 Million ≈ $144.53 Million |
€41.83 Million ≈ $48.90 Million |
0.338x | -- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.